These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30663582)

  • 1. Real-world studies no substitute for RCTs in establishing efficacy.
    Gerstein HC; McMurray J; Holman RR
    Lancet; 2019 Jan; 393(10168):210-211. PubMed ID: 30663582
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world evidence-What is it and does it matter for approval of drugs?
    Eaglstein WH
    J Am Acad Dermatol; 2018 Aug; 79(2):390-391. PubMed ID: 29410344
    [No Abstract]   [Full Text] [Related]  

  • 3. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.
    Corrigan-Curay J; Sacks L; Woodcock J
    JAMA; 2018 Sep; 320(9):867-868. PubMed ID: 30105359
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?
    Slattery J; Kurz X
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1336-1340. PubMed ID: 32301230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?
    Franklin JM; Schneeweiss S
    Clin Pharmacol Ther; 2017 Dec; 102(6):924-933. PubMed ID: 28836267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cohort multiple randomized controlled trial design: a valid and efficient alternative to pragmatic trials?
    van der Velden JM; Verkooijen HM; Young-Afat DA; Burbach JP; van Vulpen M; Relton C; van Gils CH; May AM; Groenwold RH
    Int J Epidemiol; 2017 Feb; 46(1):96-102. PubMed ID: 27118559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?
    Dal-Ré R; Janiaud P; Ioannidis JPA
    BMC Med; 2018 Apr; 16(1):49. PubMed ID: 29615035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials.
    Wang SV; Schneeweiss S; Gagne JJ; Evers T; Gerlinger C; Desai R; Najafzadeh M
    Clin Pharmacol Ther; 2019 May; 105(5):1156-1163. PubMed ID: 30107034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial design issues in schizophrenic research.
    Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentary.
    Girman CJ; Ritchey ME; Zhou W; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):439-442. PubMed ID: 30515910
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized trials analyzed as observational studies.
    Hernán MA; Hernández-Díaz S; Robins JM
    Ann Intern Med; 2013 Oct; 159(8):560-2. PubMed ID: 24018844
    [No Abstract]   [Full Text] [Related]  

  • 13. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review.
    Vonbank A; Drexel H; Agewall S; Lewis BS; Dopheide JF; Kjeldsen K; Ceconi C; Savarese G; Rosano G; Wassmann S; Niessner A; Schmidt TA; Saely CH; Baumgartner I; Tamargo J
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):230-236. PubMed ID: 30099530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquiring Surgical Knowledge: Sound Methodology and Transparent Reporting.
    Buie WD
    Dis Colon Rectum; 2017 Jun; 60(6):565-566. PubMed ID: 28481849
    [No Abstract]   [Full Text] [Related]  

  • 15. Using real world data to support regulatory approval of drugs in rare diseases: A review of opportunities, limitations & a case example.
    Gross AM
    Curr Probl Cancer; 2021 Aug; 45(4):100769. PubMed ID: 34247834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Series: Pragmatic trials and real world evidence: Paper 6. Outcome measures in the real world.
    Welsing PM; Oude Rengerink K; Collier S; Eckert L; van Smeden M; Ciaglia A; Nachbaur G; Trelle S; Taylor AJ; Egger M; Goetz I;
    J Clin Epidemiol; 2017 Oct; 90():99-107. PubMed ID: 28502810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational studies: why are they so important?
    Mariani AW; Pêgo-Fernandes PM
    Sao Paulo Med J; 2014; 132(1):1-2. PubMed ID: 24474072
    [No Abstract]   [Full Text] [Related]  

  • 18. Observational studies versus RCTs: what about socioeconomic factors?
    Rosén M; Axelsson S; Lindblom J
    Lancet; 2009 Jun; 373(9680):2026. PubMed ID: 19524779
    [No Abstract]   [Full Text] [Related]  

  • 19. How to generalize efficacy results of randomized trials: recommendations based on a systematic review of possible approaches.
    Post PN; de Beer H; Guyatt GH
    J Eval Clin Pract; 2013 Aug; 19(4):638-43. PubMed ID: 22862884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Series: Pragmatic trials and real world evidence: Paper 5. Usual care and real life comparators.
    Zuidgeest MGP; Welsing PMJ; van Thiel GJMW; Ciaglia A; Alfonso-Cristancho R; Eckert L; Eijkemans MJC; Egger M;
    J Clin Epidemiol; 2017 Oct; 90():92-98. PubMed ID: 28694123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.